Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc

Bullboard Posts

Comment by boozehound3on Jun 27, 2019 8:59pm

32 Views

Post# 29872202

RE:Mackie rates Spec buy PT $8.70 - research note

there it is    what a clown    everyone sure ran out and bought this thing because of all the buy recommendations

told you all    you will never learn    pure market manipulation

jan needs money for next years salary and start the bs all over again

she is going to need shoes for all the door to door selling she will have to do

love it    all the bs pumpers are gone

Bullboard Posts

What will the U.S. election results mean for Canada?